Frederick, MD – On July 24, 2024, the U.S. Department of Defense (DoD) fulfilled the final fiscal year (FY) 2024 delivery of 626,870 doses of the U.S. Food and Drug Administration (FDA)-approved BioThrax® (Anthrax Vaccine Adsorbed), a pre-exposure prophylaxis (PrEP) for anthrax disease. This marks the completion of the first annual delivery – part of a larger procurement contract – which showcases the DoD’s ongoing commitment to vaccine readiness for active-duty service members to support mission needs.
Led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), on behalf of the DoD and the Defense Health Agency, the $235.8 million, 10-year, sole-source, indefinite delivery/indefinite quantity (ID/IQ) contract with Emergent Biosolutions, Inc., was awarded on January 09, 2024, for use by all branches of service over the next 10 years.